U.S. FDA Head Faces Grilling Over China’s Heparin
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA Commissioner Andrew C. von Eschenbach faced a tough line of questioning from members of the House Energy & Commerce Subcommittee on Oversight and Investigations during an April 22 hearing on the agency's foreign drug inspection program